NKE heads into its June 25 earnings release with a notable reversal in options positioning — the bullish tilt that defined the pre-earnings setup two days ago has given way to something more defensive as the stock slides further.
The clearest change is in the options market. The put/call ratio has jumped to 0.79, now nearly 2.8 standard deviations above its 20-day average of 0.71 — a complete about-face from the 0.67 reading flagged in Monday's earnings preview. That prior note highlighted unusually hot call demand; what's arrived instead is a rush for downside protection. The PCR is now approaching its 52-week high of 0.97, suggesting traders have shifted from positioning for a bounce to hedging against another ugly print. The stock has fallen 5.9% on the week to $42.38, amplifying the urgency of that hedging demand.
Short interest tells a somewhat different story, though the direction has turned. Shorts rebuilt positions sharply this week — SI rose 7.4% over seven days to 4.1% of the free float, reversing the covering trend that had been in place through most of June. That's still well below the June 1 peak above 5%, and the borrow market remains loose: availability is running at 872%, meaning roughly eight shares are available for every one lent out. Cost to borrow has actually eased 34% over the week to 0.39%. There is no squeeze dynamic here. The short rebuilding looks tactical — positioning for the print — not a structural conviction call. Overall, the lending market still offers no meaningful friction for new short sellers if they want to add after results.
The Street's posture is unambiguous. Goldman Sachs lowered its target from $52 to $46 today while holding Neutral, and Evercore ISI went further, downgrading NKE to In-Line from Outperform with a new $46 target. Both cuts arrived the day before earnings. RBC cut from Outperform to Sector Perform on June 10, and Wells Fargo, Citi, UBS, and HSBC have all trimmed targets in recent weeks. The consensus now sits at Hold across 12 buys and 23 holds, with a mean price target of $58.72 — a 39% implied premium to the current price that reflects where analysts want the stock to be, not where they think it's going near-term. The bull case centres on wholesale rebuilding and direct-to-consumer margin recovery. The bear case points to slow product innovation, continued market-share losses, and management execution risk. The EPS momentum factor score ranks in the 99th percentile over 30 days — the company has been consistently beating lowered estimates — but analyst recommendation divergence scores just 2 out of 100, about as bearish as consensus gets.
The insider register offers a modest counterweight. CEO Elliott Hill purchased nearly $1 million of stock at $42.27 in April, joined by Lead Independent Director Tim Cook, who bought $1.06 million at $42.43, and two other board members. Those buys were made at prices very close to where the stock trades today. More recently, an EVP and the COO both sold in June — small amounts, likely scheduled — but the net 90-day insider position is firmly positive at roughly $4.4 million in net purchases. The founder family's combined stake above 20% hasn't moved.
History sets a stark baseline for tomorrow's print. Last quarter's earnings — reported March 31 — sent NKE down 12.9% the next day and 16.7% over the following five sessions. The quarter before that produced a more contained 2% single-day decline. The pattern is lopsided: the downside reaction to a bad print is severe. With the options market now fully repriced toward protection, tomorrow's number will determine whether the defensive repositioning of the past 24 hours was well-timed or an overreaction to a stock that has already priced in significant pain.
See the live data behind this article on ORTEX.
Open NKE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
